All updated as on -
The worldwide MicroRNA market was worth USD 215.8 mln in 2022, and is forecast to reach USD 613.7 mln by 2030, a CAGR of 15.4% between 2023 and 2030. There has been a consistent movement towards a therapeutic approach to treating and diagnosing disease as research on mammalian MicroRNAs expanded in the context of chronic disorders. Mutations in microRNAs (miRNAs) have been linked to a variety of diseases, and inhibitors and mimics of these miRNAs provide hope for treatment.
Cancer, liver disease, neurological disease, viral disease, coronary heart disease, and metabolic disease are only some of the chronic conditions that are being diagnosed and treated with miRNAs. For instance, oncogenes are usually thought to be overexpressed miRNAs in malignancies. Certain cancer cells express these at extremely low levels, which often inhibits tumour growth. The term "tumour suppressor miRNAs" refers to this class of microRNAs. One of these miRNAs that inhibits tumour growth is called Let-7. Consequently, the therapeutic potential of miRNAs in a wide range of chronic diseases is a key factor in driving the expansion of the MicroRNA market. microRNAs are a type of non-coding RNA that is abundant in a wide range of organisms, including plants, animals, and even viruses. Through post-transcriptional and RNA silencing mechanisms, they are crucial in regulating gene expression. They are gaining popularity in the medical industry because of the positive effects they have on treating and diagnosing chronic diseases like cancer, heart disease, and liver ailment.
Significant advances in microRNA technology are emerging as a result of the current technological revolution in microRNA research. Recent advances in the core phases of microRNA expression profiling, target gene identification, and validation have motivated manufacturers and researchers to create novel solutions. A good example is the HTG EdgeSeq mouse microRNA whole transcriptome test, which was just released by HTG Molecular Diagnostics, Inc. It is a comprehensive panel for microRNA expression profiling with applications in both preclinical functional investigations and translational medicine. There has been a consistent movement towards a therapeutic approach to treating and diagnosing disease as research on mammalian MicroRNAs expanded in the context of chronic disorders. Mutations in microRNAs (miRNAs) have been linked to a variety of diseases, and inhibitors and mimics of these miRNAs provide hope for treatment.
Cancer, liver disease, neurological disease, viral disease, coronary heart disease, and metabolic disease are only some of the chronic conditions that are being diagnosed and treated with miRNAs. For instance, oncogenes are usually thought to be overexpressed miRNAs in malignancies. Certain cancer cells express these at extremely low levels, which often inhibits tumour growth. The term "tumour suppressor miRNAs" refers to this class of microRNAs. One of these miRNAs that inhibits tumour growth is called Let-7. Consequently, the therapeutic potential of miRNAs in a wide range of chronic diseases is a key factor in driving the expansion of the MicroRNA market.
The use of miRNA in both basic and medical research is expanding thanks to ongoing investigations and clinical trials. There is mounting evidence that miRNAs can be used to significantly improve nearly every aspect of human health, whether as modulators of drug resistance, biomarkers for pathogenic disorders, or therapeutic interventions themselves. Therefore, one of the significant factors propelling the miRNA market growth during the forecast period is the rising number of clinical trials examining the usefulness of miRNA in the treatment of many chronic illnesses. Clinical trials using miRNA mimic TargomiRs, designed to treat patients with recurrent thoracic cancer, were undertaken in May 2016, as reported by the Future Medicine Journal.
Multiple clinical uses can reap the benefits of miRNA. It is used to treat a variety of long-term conditions, including cancer, heart disease, kidney illness, etc. The question of their safety and toxicity, however, persists. As a result, many pharmaceutical firms have put an end to human testing for their innovative miRNA-based medicines. In September 2016, for instance, Mirna Therapeutics, Inc., a pharmaceutical firm in the early stages of development, stated that it would end the Phase 1 research of MRX34, an experimental treatment for several malignancies. Due to many immune-related serious adverse events (SAE) seen in patients receiving MRX34 throughout the trial, the company voluntarily terminated recruitment and treatment.
Report Coverage
Global MicroRNA research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global MicroRNA report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and MicroRNA competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key MicroRNA market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global MicroRNA market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, MicroRNA market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Merck KgaA; Thermo Fisher Scientific, Inc.; Horizon Discovery Ltd.; Synlogic; QIAGEN; GeneCopoeia, Inc.; New England Biolabs; Quantabio; NanoString; BioGenex; SeqMatic LLC; Miltenyi Biotec; Sistemic Scotland Limited; Biodynamics Laboratory Inc; OriGene Technologies, Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global MicroRNA market based on the below-mentioned segments:
Global MicroRNA Market, By Type
Instruments
Kits & Reagents
Global MicroRNA market, By Application
Isolation & Purification
Detection & Quantification
Disease Diagnostics
Others
Global MicroRNA Market, By End User
Pharma & Biotech Companies
Academic & Research Institutes
Healthcare Facilities
Others
Global MicroRNA market, Regional Analysis
Cancer, liver disease, neurological disease, viral disease, coronary heart disease, and metabolic disease are only some of the chronic conditions that are being diagnosed and treated with miRNAs. For instance, oncogenes are usually thought to be overexpressed miRNAs in malignancies. Certain cancer cells express these at extremely low levels, which often inhibits tumour growth. The term "tumour suppressor miRNAs" refers to this class of microRNAs. One of these miRNAs that inhibits tumour growth is called Let-7. Consequently, the therapeutic potential of miRNAs in a wide range of chronic diseases is a key factor in driving the expansion of the MicroRNA market. microRNAs are a type of non-coding RNA that is abundant in a wide range of organisms, including plants, animals, and even viruses. Through post-transcriptional and RNA silencing mechanisms, they are crucial in regulating gene expression. They are gaining popularity in the medical industry because of the positive effects they have on treating and diagnosing chronic diseases like cancer, heart disease, and liver ailment.
Significant advances in microRNA technology are emerging as a result of the current technological revolution in microRNA research. Recent advances in the core phases of microRNA expression profiling, target gene identification, and validation have motivated manufacturers and researchers to create novel solutions. A good example is the HTG EdgeSeq mouse microRNA whole transcriptome test, which was just released by HTG Molecular Diagnostics, Inc. It is a comprehensive panel for microRNA expression profiling with applications in both preclinical functional investigations and translational medicine. There has been a consistent movement towards a therapeutic approach to treating and diagnosing disease as research on mammalian MicroRNAs expanded in the context of chronic disorders. Mutations in microRNAs (miRNAs) have been linked to a variety of diseases, and inhibitors and mimics of these miRNAs provide hope for treatment.
Cancer, liver disease, neurological disease, viral disease, coronary heart disease, and metabolic disease are only some of the chronic conditions that are being diagnosed and treated with miRNAs. For instance, oncogenes are usually thought to be overexpressed miRNAs in malignancies. Certain cancer cells express these at extremely low levels, which often inhibits tumour growth. The term "tumour suppressor miRNAs" refers to this class of microRNAs. One of these miRNAs that inhibits tumour growth is called Let-7. Consequently, the therapeutic potential of miRNAs in a wide range of chronic diseases is a key factor in driving the expansion of the MicroRNA market.
The use of miRNA in both basic and medical research is expanding thanks to ongoing investigations and clinical trials. There is mounting evidence that miRNAs can be used to significantly improve nearly every aspect of human health, whether as modulators of drug resistance, biomarkers for pathogenic disorders, or therapeutic interventions themselves. Therefore, one of the significant factors propelling the miRNA market growth during the forecast period is the rising number of clinical trials examining the usefulness of miRNA in the treatment of many chronic illnesses. Clinical trials using miRNA mimic TargomiRs, designed to treat patients with recurrent thoracic cancer, were undertaken in May 2016, as reported by the Future Medicine Journal.
Multiple clinical uses can reap the benefits of miRNA. It is used to treat a variety of long-term conditions, including cancer, heart disease, kidney illness, etc. The question of their safety and toxicity, however, persists. As a result, many pharmaceutical firms have put an end to human testing for their innovative miRNA-based medicines. In September 2016, for instance, Mirna Therapeutics, Inc., a pharmaceutical firm in the early stages of development, stated that it would end the Phase 1 research of MRX34, an experimental treatment for several malignancies. Due to many immune-related serious adverse events (SAE) seen in patients receiving MRX34 throughout the trial, the company voluntarily terminated recruitment and treatment.
Report Coverage
Global MicroRNA research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global MicroRNA report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and MicroRNA competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key MicroRNA market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Merck KgaA; Thermo Fisher Scientific, Inc.; Horizon Discovery Ltd.; Synlogic; QIAGEN; GeneCopoeia, Inc.; New England Biolabs; Quantabio; NanoString; BioGenex; SeqMatic LLC; Miltenyi Biotec; Sistemic Scotland Limited; Biodynamics Laboratory Inc; OriGene Technologies, Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of MicroRNA Market from 2021 to 2030.
- Market Forecast for MicroRNA Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, MicroRNA competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on MicroRNA
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global MicroRNA market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, MicroRNA market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Merck KgaA; Thermo Fisher Scientific, Inc.; Horizon Discovery Ltd.; Synlogic; QIAGEN; GeneCopoeia, Inc.; New England Biolabs; Quantabio; NanoString; BioGenex; SeqMatic LLC; Miltenyi Biotec; Sistemic Scotland Limited; Biodynamics Laboratory Inc; OriGene Technologies, Inc.
Primary Target Market
- Market Players of MicroRNA
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global MicroRNA market based on the below-mentioned segments:
Global MicroRNA Market, By Type
Instruments
Kits & Reagents
Global MicroRNA market, By Application
Isolation & Purification
Detection & Quantification
Disease Diagnostics
Others
Global MicroRNA Market, By End User
Pharma & Biotech Companies
Academic & Research Institutes
Healthcare Facilities
Others
Global MicroRNA market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive microrna market market research and competitor analysis for your business to help you develop more profound insights into the microrna market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the microrna market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.